tiprankstipranks
Trending News
More News >

Promising Clinical Data and Ongoing Trials Justify Buy Rating for Exelixis’s Zanzalintinib

Promising Clinical Data and Ongoing Trials Justify Buy Rating for Exelixis’s Zanzalintinib

William Blair analyst Andy Hsieh has maintained their bullish stance on EXEL stock, giving a Buy rating today.

Don’t Miss TipRanks’ Half Year Sale

Andy Hsieh has given his Buy rating due to a combination of factors, primarily focusing on the promising clinical data from Exelixis’s zanzalintinib. The results from the Phase Ib STELLAR-002 trial, presented at the 2025 ASCO annual meeting, showed a strong response rate in combination with Opdualag for frontline clear-cell renal cell carcinoma, which is comparable to the efficacy of the parent compound, Cabometyx.
Furthermore, Hsieh is optimistic about the ongoing Phase III studies, STELLAR-303 and STELLAR-304, which are expected to yield positive results in the latter half of the year. These studies target third-line colorectal cancer and treatment-naïve non-clear-cell RCC, respectively. The consistent performance of zanzalintinib in clinical trials underpins the confidence in Exelixis’s potential for future success, justifying the Buy rating.

According to TipRanks, Hsieh is a 4-star analyst with an average return of 5.5% and a 44.81% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Skye Bioscience, Exelixis, and Cardiff Oncology.

Disclaimer & DisclosureReport an Issue

1